Context:
Data suggests that advanced liver disease is usually recognised very late and deaths from liver disease continue to rise.
Solution:
Liver Toolkit
The exclusive education programme for NHS Wales was adopted across all Health Boards and is formally endorsed by the British Liver Trust.
Wales is the only country that delivers assertive fibrosis testing on a population basis worldwide and, in addition, is the only country to provide a specific education and support package underpinning this strategy. The toolkit provides digital support for practitioners, promoting practices and behaviour change principles that result in improved outcomes and ultimately reduce the burden on the health system.
The Liver toolkit for NHS Wales consisted of:
1
Healthcare Professional Platform
2
Commissioner Data Reporting
By using implementation science and individual behavioural science methodologies, the toolkit achieves reach and adoption whilst achieving outcomes. This approach ensures seamless system installation without the need for additional resources or staffing. By practically supporting existing services, rather than imposing fundamental change, the toolkit minimises resistance, ensures sustainability, and achieves population-level reach and scalability.
Outcomes:
Liver Toolkit
A world first
Wales is the only country that delivers assertive fibrosis testing of a population basis worldwide.
The only country to provide education and support package
In addition, Wales is the only country to provide a specific education and support package underpinning this strategy.
Near-perfect coverage
Where the toolkit has been implemented, including on a National basis, we see coverage of 98% of GP practices that have healthcare professionals using the toolkit.
"ICST supports the broader aspiration of the LDIG (and indeed of “A Healthier Wales”) in terms of providing care closer to home and providing more care in community or primary care settings. This is initially envisaged as an “outreach” model from secondary care given the historic lack of priority afforded to liver disease within healthcare services, primary care especially”
Dr Andrew Yeoman
National Clinical Lead for Liver Disease, NHS Wales
“The All Wales Liver Pathway manages to differentiate between low and high risk of liver disease, a lot more succinctly than we might do otherwise. This will present a great tool for us to reference against, and for us to be embedding to this improved care.”
Dr Steve Short
GP